Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2006-10-24
2006-10-24
Kumar, Shailendra (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C544S166000, C544S329000
Reexamination Certificate
active
07125997
ABSTRACT:
The invention is directed to novel biaryl derivatives, to the uses of these compounds in various medicinal applications, including the treatment, prevention and control of proliferative diseases such as tumors, and to pharmaceutical compositions comprising these compounds. Compounds of the invention can be used to treat or prevent diseases or disorders that involve the activity of MIF-1 and/or adenosine kinase.
REFERENCES:
patent: 2766233 (1956-10-01), Kartinos et al.
patent: 3029241 (1962-04-01), Otis et al.
patent: 4336382 (1982-06-01), Fahrenholtz et al.
patent: 4931444 (1990-06-01), Van Wauwe et al.
patent: 5728835 (1998-03-01), Aoki et al.
patent: 6013659 (2000-01-01), Goldfarb et al.
patent: 6331555 (2001-12-01), Hirth et al.
patent: 6770667 (2004-08-01), Ito et al.
patent: 7001905 (2006-02-01), Biwersi et al.
patent: 0 662 351 (1987-09-01), None
patent: 3408127 (1984-09-01), None
Valgeirsson et al. 2-Arylureidobenzoic Acids: Selective Non-competitive Antagonists for the Homomeric Kainate Receptor Subtype GluR5. J. Med. Chem. 2003, vol. 46, No. 26, pp. 5834-5843.
Chyba Jason
Devereax Quinn
Hampton Garret
King Fred
Genomics Institute of the Novartis Research Foundation
IRM LLC
Kumar Shailendra
Reid Scott W.
LandOfFree
Differential tumor cytotoxicity compounds and compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Differential tumor cytotoxicity compounds and compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Differential tumor cytotoxicity compounds and compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3674758